Ana Radeljevic - 06 Jun 2023 Form 4 Insider Report for MERRIMACK PHARMACEUTICALS INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 06 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2023, 16:15:31 UTC
Prior SEC filing: 09 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Ana Radeljevic

Key filing fact

Ana Radeljevic filed Form 4 for MERRIMACK PHARMACEUTICALS INC on 08 Jun 2023.

Key facts

This page summarizes Ana Radeljevic's Form 4 filing for MERRIMACK PHARMACEUTICALS INC.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2023, 16:15.

Change

Previous filing in this sequence was filed on 09 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MACK transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,000
Change %: +100%
Price: $0.000000
Shares after: 14,000
Date: 06 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,000
Exercise price: $12.48
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests as to 1/4th of the total number of shares on 7/1/23 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 4/1/24.